Abgenix, Inc. (ABGX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John McCarthy who wrote (514)	11/3/2005 11:30:18 PM
From: Miljenko Zuanic	Read Replies (2) of 590

John, It is not my intention to compare E trials results with P report one. As you mentioned P trial was for irino and/or oxaly refractory, while E trial was irino refractory. Also, there are many other things that make comparison very, very hard. I mentioned early that I do not believe that P will be superior/inferior to E, and I still believe that those two drugs are similar in activity (as results from other trials indicate). No doubt, P trial is positive and none can take off 46% difference when 33% was target. However, I do not see purpose when AMGN is "hiding" under 46% difference and not giving true numbers. Miljenko PS: X's and Y's are to quantify (if possible) drug medical benefit, not sticking to pure statistic.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next